ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.00
0.35%
S&P ASX All Technology
3,067.50
0.14%
Brent Oil
82.585
0.00%
US Dollar vs AUD
1.50989
0.00%
Bitcoin
60,799.60
0.01%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sana Biotechnology Inc (SANA)

  7. Sana Biotechnology Inc (SANA) News

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SANA
DateTimeSourceHeadlineSymbolCompany
09/05/202406:49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SANASana Biotechnology Inc
09/05/202406:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SANASana Biotechnology Inc
09/05/202406:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
09/05/202406:05GlobeNewswire Inc.Sana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
07/05/202406:05GlobeNewswire Inc.Sana Biotechnology to Present at May and June 2024 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
09/03/202408:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
09/03/202408:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
01/03/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
01/03/202408:05GlobeNewswire Inc.Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
29/02/202408:05GlobeNewswire Inc.Sana Biotechnology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:SANASana Biotechnology Inc
15/02/202408:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
14/02/202408:05GlobeNewswire Inc.Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHPNASDAQ:SANASana Biotechnology Inc
13/02/202408:05GlobeNewswire Inc.Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:SANASana Biotechnology Inc
09/02/202409:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
09/02/202408:49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SANASana Biotechnology Inc
08/02/202417:22GlobeNewswire Inc.Sana Biotechnology Announces Pricing of Upsized Public OfferingNASDAQ:SANASana Biotechnology Inc
08/02/202413:59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:SANASana Biotechnology Inc
08/02/202409:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SANASana Biotechnology Inc
08/02/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
08/02/202408:01GlobeNewswire Inc.Sana Biotechnology Announces Proposed Public Offering of Common StockNASDAQ:SANASana Biotechnology Inc
10/01/202401:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
06/01/202401:00GlobeNewswire Inc.Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell MalignanciesNASDAQ:SANASana Biotechnology Inc
04/01/202408:05GlobeNewswire Inc.Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
19/12/202308:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SANASana Biotechnology Inc
16/12/202308:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SANASana Biotechnology Inc
12/12/202308:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SANASana Biotechnology Inc
12/12/202301:00GlobeNewswire Inc.Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual MeetingNASDAQ:SANASana Biotechnology Inc
02/12/202308:05GlobeNewswire Inc.Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune SystemNASDAQ:SANASana Biotechnology Inc
28/11/202311:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:SANASana Biotechnology Inc
22/11/202301:00GlobeNewswire Inc.Sana Biotechnology to Present at November and December 2023 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA

Your Recent History

NYSE
KO
Coca Cola
FX
AUDJPY
AUD vs Yen
CCOM
SILVER
SILVER
SPI
SP500
S&P 500
ASX
AMP
AMP
ASX
XJO
S&P ASX 200
NYSE
MRK
Merck
NYSE
MCD
McDonalds
FX
GBPAUD
Sterling vs AUD
ASX
FMG
Fortescue
FX
AUDUSD
AUD vs US Dollar
ASX
WOW
Woolworths
COIN
BTCUSD
Bitcoin
FTSE
UKX
FTSE 100
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved